Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Mar;41(3):407–414. doi: 10.1038/bjc.1980.64

Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect.

H D Mitcheson, T E Sadler, J E Castro
PMCID: PMC2010249  PMID: 7387830

Abstract

The murine dose of i.v. C. parvum (466 microgram) was compared with a single, low, human-equivalent dose of 70 microgram and with repeated weekly low doses. All treatments increased the antibody titre against C. parvum (CP). However, repeated doses stimulated a much higher titre than single doses. In all treated animals spleen weight peaked at 2 weeks and then fell. A single low dose caused a 3-fold increase, a single high dose or multiple low doses a 6-fold increase. Liver weight changes followed a similar pattern. Hepatosplenomegaly was prolonged by multiple doses. The effects of these treatments on Lewis tumour metastases were studied. A single high dose and a single low dose on the day of tumour implantation (Day 0) were equally effective at inhibiting pulmonary metastases. Repeated low doses starting on Day 0 were no more effective than a single dose. The effect of CP on survival after primary-tumour excision on Day 10 was observed. Low dose CP on Day 7 doubled the harmonic mean of survival time. Repeated doses were no more effective than a single dose. Low-dose prophylaxis up to 2 weeks before tumour significantly inhibited metastases. However, when repeated low-dose prophylaxis was combined with a single low dose on Day 0, the anti-metastatic effect was abrogated. This neutralization of the anti-metastatic effect of CP given on Day 0 was found to persist after a 13-week treatment-free interval. Possible mechanisms for this phenomenon are discussed.

Full text

PDF
407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlam C., Scott M. T. Lympho-reticular stimulatory properties of Corynebacterium parvum and related bacteria. J Med Microbiol. 1973 Aug;6(3):261–274. doi: 10.1099/00222615-6-3-261. [DOI] [PubMed] [Google Scholar]
  2. Baldwin R. W., Robins R. A. Factors interfering with immunological rejection of tumours. Br Med Bull. 1976 May;32(2):118–123. doi: 10.1093/oxfordjournals.bmb.a071342. [DOI] [PubMed] [Google Scholar]
  3. Cederholm-Williams S. A., King A., Allington M. J., Gill P. G., Sharp A. A., Britton B. J. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man. Br J Cancer. 1978 Jun;37(6):1074–1077. doi: 10.1038/bjc.1978.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fisher B., Wolmark N., Saffer E., Fisher E. R. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors. Cancer. 1975 Jan;35(1):134–143. doi: 10.1002/1097-0142(197501)35:1<134::aid-cncr2820350119>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  5. Halpern B. N., Biozzi G., Stiffel C., Mouton D. Inhibition of tumour growth by administration of killed corynebacterium parvum. Nature. 1966 Nov 19;212(5064):853–854. doi: 10.1038/212853a0. [DOI] [PubMed] [Google Scholar]
  6. Israël L., Edelstein R., Depierre A., Dimitrov N. Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings. J Natl Cancer Inst. 1975 Jul;55(1):29–33. doi: 10.1093/jnci/55.1.29. [DOI] [PubMed] [Google Scholar]
  7. James S. E., Salsbury A. J. Effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res. 1974 Apr;34(4):839–842. [PubMed] [Google Scholar]
  8. Lampert I. A., Jones P. D., Sadler T. E., Castro J. E. Intravascular coagulation resulting from intravenous injection of C. parvum in mice. Br J Cancer. 1977 Jul;36(1):15–22. doi: 10.1038/bjc.1977.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mathé G., Florentin I., Olsson L., Bruley-Rosset M., Schulz J., Kiger N., Orbach-Arbouys S., Schwarzenberg L., Pouillart P., de Vassal F. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy. Cancer Treat Rep. 1978 Nov;62(11):1613–1621. [PubMed] [Google Scholar]
  10. McBride W. H., Dawes J., Dunbar N., Ghaffar A., Woodruff M. F. A comparative study of anaerobic Coryneforms. Attempts to correlate their anti-tumour activity with their serological properties and ability to stimulate the lymphoreticular system. Immunology. 1975 Jan;28(1):49–58. [PMC free article] [PubMed] [Google Scholar]
  11. Milas L., Basic I., Kogelnik H. D., Withers H. R. Effects of Corynebacterium granulosum on weight and histology of lymphoid organs, response to mitogens, skin allografts, and a syngeneic fibrosarcoma in mice. Cancer Res. 1975 Sep;35(9):2365–2374. [PubMed] [Google Scholar]
  12. Milas L., Scott M. T. Antitumor activity of Corynebacterium parvum. Adv Cancer Res. 1978;26:257–306. doi: 10.1016/s0065-230x(08)60090-1. [DOI] [PubMed] [Google Scholar]
  13. Mitcheson H. D., Castro J. E. Clinical studies with Corynebacterium parvum. Dev Biol Stand. 1977 Apr 13;38:509–514. [PubMed] [Google Scholar]
  14. Proctor J., Rudenstam C. M., Alexander P. Increased incidence of lung metastases following treatment of rats bearing hepatomas with irradiated tumour cells and the benefical effect of Corynebacterium parvum in this system. Biomedicine. 1973 Jun 20;19(6):248–252. [PubMed] [Google Scholar]
  15. SUGIURA K., STOCK C. C. Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors. Cancer Res. 1955 Jan;15(1):38–51. [PubMed] [Google Scholar]
  16. Sadler T. E., Castro J. E. The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases. Br J Surg. 1976 Apr;63(4):292–296. doi: 10.1002/bjs.1800630410. [DOI] [PubMed] [Google Scholar]
  17. Scott M. T. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection. J Natl Cancer Inst. 1974 Sep;53(3):855–860. doi: 10.1093/jnci/53.3.855. [DOI] [PubMed] [Google Scholar]
  18. Scott M. T. Corynebacterium parvum as an immunotherapeutic anticancer agent. Semin Oncol. 1974 Dec;1(4):367–378. [PubMed] [Google Scholar]
  19. Scott M. T., Warner S. L. The accumulated effects of repeated systemic or local injections of low doses of Corynebacterium parvum in mice. Cancer Res. 1976 Apr;36(4):1335–1338. [PubMed] [Google Scholar]
  20. Smith S. E., Scott M. T. Biological effects of Corynebacterium parvum. 3. Amplification of resistance and impairment of active immunity to murine tumours. Br J Cancer. 1972 Oct;26(5):361–367. doi: 10.1038/bjc.1972.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thatcher N., Crowther D. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. Dev Biol Stand. 1977 Apr 13;38:449–453. [PubMed] [Google Scholar]
  22. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641–645. doi: 10.1093/jnci/36.4.641. [DOI] [PubMed] [Google Scholar]
  23. Woodruff M. F., Boak J. L. Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts. Br J Cancer. 1966 Jun;20(2):345–355. doi: 10.1038/bjc.1966.42. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES